Cargando…
Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies
The synucleinopathies Parkinson’s disease (PD) and Multiple system atrophy (MSA) — characterized by α-synuclein intracytoplasmic inclusions into, respectively, neurons and oligodendrocytes — are associated with impairment of the autophagy-lysosomal pathways (ALP). Increased expression of the master...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777809/ https://www.ncbi.nlm.nih.gov/pubmed/31434803 http://dx.doi.org/10.1172/jci.insight.129719 |
_version_ | 1783456671911116800 |
---|---|
author | Arotcarena, Marie-Laure Bourdenx, Mathieu Dutheil, Nathalie Thiolat, Marie-Laure Doudnikoff, Evelyne Dovero, Sandra Ballabio, Andrea Fernagut, Pierre-Olivier Meissner, Wassilios G. Bezard, Erwan Dehay, Benjamin |
author_facet | Arotcarena, Marie-Laure Bourdenx, Mathieu Dutheil, Nathalie Thiolat, Marie-Laure Doudnikoff, Evelyne Dovero, Sandra Ballabio, Andrea Fernagut, Pierre-Olivier Meissner, Wassilios G. Bezard, Erwan Dehay, Benjamin |
author_sort | Arotcarena, Marie-Laure |
collection | PubMed |
description | The synucleinopathies Parkinson’s disease (PD) and Multiple system atrophy (MSA) — characterized by α-synuclein intracytoplasmic inclusions into, respectively, neurons and oligodendrocytes — are associated with impairment of the autophagy-lysosomal pathways (ALP). Increased expression of the master regulator of ALP, transcription factor EB (TFEB), is hypothesized to promote the clearance of WT α-synuclein and survival of dopaminergic neurons. Here, we explore the efficacy of targeted TFEB overexpression either in neurons or oligodendrocytes to reduce the pathological burden of α-synuclein in a PD rat model and a MSA mouse model. While TFEB neuronal expression was sufficient to prevent neurodegeneration in the PD model, we show that only TFEB oligodendroglial overexpression leads to neuroprotective effects in the MSA model. These beneficial effects were associated with a decreased accumulation of α-synuclein into oligodendrocytes through recovery of the ALP machinery. Our study demonstrates that the cell type where α-synuclein aggregates dictates the target of TFEB overexpression in order to be protective, paving the way for adapted therapies. |
format | Online Article Text |
id | pubmed-6777809 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | American Society for Clinical Investigation |
record_format | MEDLINE/PubMed |
spelling | pubmed-67778092019-10-10 Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies Arotcarena, Marie-Laure Bourdenx, Mathieu Dutheil, Nathalie Thiolat, Marie-Laure Doudnikoff, Evelyne Dovero, Sandra Ballabio, Andrea Fernagut, Pierre-Olivier Meissner, Wassilios G. Bezard, Erwan Dehay, Benjamin JCI Insight Research Article The synucleinopathies Parkinson’s disease (PD) and Multiple system atrophy (MSA) — characterized by α-synuclein intracytoplasmic inclusions into, respectively, neurons and oligodendrocytes — are associated with impairment of the autophagy-lysosomal pathways (ALP). Increased expression of the master regulator of ALP, transcription factor EB (TFEB), is hypothesized to promote the clearance of WT α-synuclein and survival of dopaminergic neurons. Here, we explore the efficacy of targeted TFEB overexpression either in neurons or oligodendrocytes to reduce the pathological burden of α-synuclein in a PD rat model and a MSA mouse model. While TFEB neuronal expression was sufficient to prevent neurodegeneration in the PD model, we show that only TFEB oligodendroglial overexpression leads to neuroprotective effects in the MSA model. These beneficial effects were associated with a decreased accumulation of α-synuclein into oligodendrocytes through recovery of the ALP machinery. Our study demonstrates that the cell type where α-synuclein aggregates dictates the target of TFEB overexpression in order to be protective, paving the way for adapted therapies. American Society for Clinical Investigation 2019-08-22 /pmc/articles/PMC6777809/ /pubmed/31434803 http://dx.doi.org/10.1172/jci.insight.129719 Text en © 2019 Arotcarena et al. http://creativecommons.org/licenses/by/4.0/ This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Arotcarena, Marie-Laure Bourdenx, Mathieu Dutheil, Nathalie Thiolat, Marie-Laure Doudnikoff, Evelyne Dovero, Sandra Ballabio, Andrea Fernagut, Pierre-Olivier Meissner, Wassilios G. Bezard, Erwan Dehay, Benjamin Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies |
title | Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies |
title_full | Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies |
title_fullStr | Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies |
title_full_unstemmed | Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies |
title_short | Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies |
title_sort | transcription factor eb overexpression prevents neurodegeneration in experimental synucleinopathies |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777809/ https://www.ncbi.nlm.nih.gov/pubmed/31434803 http://dx.doi.org/10.1172/jci.insight.129719 |
work_keys_str_mv | AT arotcarenamarielaure transcriptionfactoreboverexpressionpreventsneurodegenerationinexperimentalsynucleinopathies AT bourdenxmathieu transcriptionfactoreboverexpressionpreventsneurodegenerationinexperimentalsynucleinopathies AT dutheilnathalie transcriptionfactoreboverexpressionpreventsneurodegenerationinexperimentalsynucleinopathies AT thiolatmarielaure transcriptionfactoreboverexpressionpreventsneurodegenerationinexperimentalsynucleinopathies AT doudnikoffevelyne transcriptionfactoreboverexpressionpreventsneurodegenerationinexperimentalsynucleinopathies AT doverosandra transcriptionfactoreboverexpressionpreventsneurodegenerationinexperimentalsynucleinopathies AT ballabioandrea transcriptionfactoreboverexpressionpreventsneurodegenerationinexperimentalsynucleinopathies AT fernagutpierreolivier transcriptionfactoreboverexpressionpreventsneurodegenerationinexperimentalsynucleinopathies AT meissnerwassiliosg transcriptionfactoreboverexpressionpreventsneurodegenerationinexperimentalsynucleinopathies AT bezarderwan transcriptionfactoreboverexpressionpreventsneurodegenerationinexperimentalsynucleinopathies AT dehaybenjamin transcriptionfactoreboverexpressionpreventsneurodegenerationinexperimentalsynucleinopathies |